Assessment Status
Closed
ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how these methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system to allow for broader insurance coverage for innovative new treatments.
For questions or additional information, please contact info@icer.org.
Kaiser Permanente Center for Total Health
700 2nd St NE, Washington, DC 20002
Washington, DC
Part One: Welcoming Remarks and Panel 1 (Contextual Considerations and Ethical Issues)
Part Two: Panel 2 (Comparative Clinical Effectiveness) and Panel 3 (Other Benefits or Disadvantages)
Part Three: Panel 4 (Price, Cost-Effectiveness, and Affordability) and Adjournment
ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system, to allow for broader insurance coverage for innovative new treatments.
In addition to the Briefing Paper, the following academic papers may serve as useful pre-reading for the Summit:
Comments received during the 60-day public comment period on proposed framework changes.
ICER’s rare disease paper is available in Value in Health: https://www.sciencedirect.com/science/article/pii/S1098301518301906
Public Comments
Closed